Abstract
The aim of the study was to evaluate concentrations of IL-17 in the serum and plaque scales of psoriatic patients. We analyzed their association with the clinical activity of the disease and with body mass index (BMI). Demographic data, medical history, serum, and scale from psoriatic plaques for assessment of IL-17 were collected from all the participants. The disease severity was assessed with PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), PGA (Physician Global Assessment), NAPSI (Nail Psoriasis Severity Index), and DLQI (Dermatology Quality of Life Index) scores. Obesity was diagnosed by calculating body mass index. Serum and scale concentration of IL-17 was determined with Human IL-17A High Sensitivity ELISA kit and Human IL-17 ELISA kit. In the psoriatic patients, BMI was statistically significantly higher than in the control group. Most of the patients presented BMI higher than normal. Our study confirms that overweight is a problem among psoriatic patients. A significant positive correlation between the IL-17 serum and scale concentrations and psoriasis severity indicates that IL-17 can be used as the marker of disease severity. More data from human studies can be crucial for understanding that relationship between IL-17, psoriasis, and obesity.
Highlights
Psoriasis is a common chronic disease with the prevalence from 0.91 in the USA to 8.5% in Norway, whose new pathogenesis aspects are constantly being explored [1, 2]
Most of our patients presented body mass index (BMI) higher than normal: 8 (38%) patients were classified as overweight, and 8 (38%) patients were classified as obese (BMI above 30)
The group of male patients with severe psoriasis presented in this study has BMI higher than in the control group. 76% of patients presented BMI higher than normal
Summary
Psoriasis is a common chronic disease with the prevalence from 0.91 in the USA to 8.5% in Norway, whose new pathogenesis aspects are constantly being explored [1, 2]. Since 2005, when Th17, the new subtype of T helper cells was discovered, many studies are conducted to find the role of IL-17 in psoriasis and other diseases’ pathogenesis [6,7,8,9]. IL17 has a proinflammatory activity inducing the expression of proinflammatory cytokines, colony-stimulating factors, and chemokines from dendritic cells, neutrophils, T cells, monocyte/macrophages, and epithelial cells [6, 12, 13]. IL-6 is overproduced by adipocytes and macrophages in visceral adipose tissue [17], what influences on IL-17 production. There is evidence of the inhibitory effect of IL-17 on adipogenesis [14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
